CytoMed Therapeutics Ltd
Close on Oct 19, 2026
About CytoMed Therapeutics
Pharmaceutical Preparations, SIC 2834
CytoMed Therapeutics Limited is a biopharmaceutical company focused on developing cell-based immunotherapies and related healthcare solutions. The company operates primarily through two segments: immune cell therapy and umbilical cord blood unit (CBU) banking services alongside related therapeutic applications. Through its subsidiaries, it engages in research, development, and provision of specialized cellular products, intellectual property licensing, and depository services for biological materials to serve clinical and therapeutic healthcare clients.
The company maintains operational and corporate activities across Singapore and Malaysia, utilizing specialized laboratory equipment, freehold land, and leased operational premises to conduct research and banking activities. Its subsidiaries include CytoMed Therapeutics (Malaysia) Sdn. Bhd., Longevity Bank Pte. Ltd., Advance Cancer Centre Pte. Ltd., IPSC Depository Sdn. Bhd., and Puricell Lab Pte. Ltd. CytoMed Therapeutics Limited maintains its principal executive offices and headquarters in Singapore.
Summary of the business section of CytoMed Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CytoMed Therapeutics Ltd
- Founded
- 2018
- Headquarters
- 1 Commonwealth Lane, U0
- Address
- #08-22 One Commonwealth 149544
- Phone
- 603824911
- Website
- cytomed.sg
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- U0
- Fiscal year ends
- December 31
- Auditor
- WWC, P.C., San Mateo, California
Stock & identifiers
- Ticker
- GDTC
- Exchange
- Nasdaq
- IPO date
- Apr 17, 2023
- Shares outstanding
- 12M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1873093
- CUSIP
- Y1R80M106
- ISIN
- USY1R80M1067
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yvonne Goh | Chief Financial Officer | 25,781 |
| Yoong Ying Tan | Chief Corporate Officer | 25,781 |
| Chee Kong Choo | Director | 2,899,746 |
| Keng Kiat Toh | Director | 4,000 |
| Mark Kei Wei Leong | Director | – |
| Chak Hua Yew | Director | 2,469 |
Employees
Headcount reported in annual reports
“Employers with fewer than 5 employees will be granted a 6-month deferment period, making the new wage effective August 1, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 30, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 30, 2022 | Name change | Name changed from CytoMed Therapeutics Pte. Ltd. to CytoMed Therapeutics Ltd |